1
|
Parikh R, Farber HW. Response to "Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD" by Nathan et al. J Heart Lung Transplant 2024; 43:691-692. [PMID: 38158103 DOI: 10.1016/j.healun.2023.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Accepted: 12/19/2023] [Indexed: 01/03/2024] Open
Affiliation(s)
- R Parikh
- Division of Pulmonary, Critical Care and Sleep Medicine, Hartford Hospital, Hartford, Connecticut.
| | - H W Farber
- Division of Pulmonary, Sleep and Critical Care Medicine, Tufts Medical Center, Boston, Massachusetts
| |
Collapse
|
2
|
Butler EA, Parikh R, Grandi SM, Ray JG, Cohen E. ABO and Rh blood groups and risk of infection: systematic review and meta-analysis. BMC Infect Dis 2023; 23:797. [PMID: 37964217 PMCID: PMC10647048 DOI: 10.1186/s12879-023-08792-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Accepted: 11/05/2023] [Indexed: 11/16/2023] Open
Abstract
BACKGROUND Persons with non-O and Rh-positive blood types are purported to be more susceptible to infection, including SARS-CoV-2, but there remains uncertainty about the degree to which this is so for both non-viral and viral infections. METHODS We systematically reviewed Embase and PubMed from January 1st 1960 to May 31st 2022. English-language publications were selected that separately investigated the relation between ABO and/or Rh blood group and risk of SARS-CoV-2 and non-SARS-CoV-2 infection. Pooled odds ratios (ORp) and 95% confidence intervals (CI) were then generated for each. RESULTS Non-O blood groups had a higher ORp for SARS-CoV-2 than O blood groups, both within 22 case-control studies (2.13, 95% CI 1.49- 3.04) and 15 cohort studies (1.89, 95% CI 1.56- 2.29). For non-SARS-CoV-2 viral infections, the respective ORp were 1.98 (95% CI 1.49-2.65; 4 case-control studies) and 1.87 (95% CI 1.53-2.29; 12 cohort studies). For non-viral infections, the ORp were 1.56 (95% CI 0.98-2.46; 13 case-control studies) and 2.11 (95% CI 1.67-6.67; 4 cohort studies). Rh-positive status had a higher ORp for SARS-CoV-2 infection within 6 case-control studies (13.83, 95% CI 6.18-30.96) and 6 cohort studies (19.04, 95% CI 11.63-31.17), compared to Rh-negative persons. For Rh status, non-SARS-CoV-2 infections, the ORp were 23.45 (95% CI 16.28-33.76) among 7 case-control studies, and 9.25 (95% CI 2.72-31.48) within 4 cohort studies. High measures of heterogeneity were notably observed for all analyses. CONCLUSIONS Non-O and Rh-positive blood status are each associated with a higher risk of SARS-CoV-2 infection, in addition to other viral and non-viral infections.
Collapse
Affiliation(s)
- Emily Ana Butler
- Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada
- Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada
| | - Rushil Parikh
- Department of Health Sciences, Wilfrid Laurier University, Waterloo, ON, Canada
| | - Sonia M Grandi
- Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada
- Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
| | - Joel G Ray
- Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada
- Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada
| | - Eyal Cohen
- Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.
- Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada.
- Edwin S.H. Leong Centre for Healthy Children, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
| |
Collapse
|
3
|
TAN T, Parikh R, Mahapatra A, Perkins R, Go A. WCN23-0469 IgA NEPHROPATHY AND RISKS OF KIDNEY AND CARDIOVASCULAR EVENTS AND DEATH: THE KNIGHT STUDY. Kidney Int Rep 2023. [DOI: 10.1016/j.ekir.2023.02.614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023] Open
|
4
|
Parikh R, Widenmaier R, Weller R, Lecrenier N. An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac129.728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The adjuvanted recombinant zoster vaccine (RZV), first approved in 2017, has high, long-lasting efficacy against herpes zoster (HZ) and a clinically acceptable safety profile. In addition to the prevention of HZ in adults aged ≥50 years, the non-live RZV can be used from age 18 years in individuals with immunocompromised (IC) conditions. We reviewed the evolving landscape of national recommendations for RZV use.
Methods
National health authority and vaccination committee websites of countries where RZV is approved were searched in March 2022.
Results
Of 41 countries where RZV is licensed, 14 (Australia, Austria, Canada, Czech Republic, Germany, Ireland, Italy, Netherlands, New Zealand, Saudi Arabia, Spain, Switzerland, UK, US) provide national recommendations related to RZV; the majority are preferential to RZV or only recommend RZV. Overall, seven and seven countries recommend immunisation from age 50 years or 60/65 years, respectively. Of the seven countries that recommend immunisation from age 60/65 years, five recommend immunisation in individuals from age 50 years with comorbidities/IC conditions. Five countries recommend immunisation from age 18/19 years in individuals at increased risk of HZ due to immunosuppressive disease/treatment. In addition, six national recommendations refer to RZV safety and nine address prior HZ vaccination and/or infection. All recommendations outlined the RZV administration schedule.
Conclusions
Although national recommendations can inform decision making in clinical practice, RZV recommendations are not available in all licensed countries. The recommendations highlight a trend in favour of the use of RZV for the prevention of HZ in older individuals and those with IC conditions.
Main messages: An increasing number of countries are providing recommendations for the use of RZV for the prevention of HZ in older individuals and those with IC conditions.
Key messages
• An increasing number of countries are providing recommendations for the use of RZV for the prevention of HZ in older individuals.
• An increasing number of countries are providing recommendations for the use of RZV for the prevention of HZ in IC conditions.
Collapse
Affiliation(s)
- R Parikh
- Global Medical Affairs , GlaxoSmithKline, Wavre, Belgium
| | - R Widenmaier
- Global Medical Affairs , GlaxoSmithKline, Rockville, USA
| | - R Weller
- Global Medical Affairs , GlaxoSmithKline, Munich, Germany
| | - N Lecrenier
- Global Medical Affairs , GlaxoSmithKline, Wavre, Belgium
| |
Collapse
|
5
|
Lecrenier N, Parikh R, Wang C, Curran D, Widenmaier R. The impact of the COVID-19 pandemic on the incidence of herpes zoster. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac131.204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
There have been several case reports of herpes zoster (HZ) following COVID-19 disease and vaccination. We conducted a non-systematic literature search to elucidate the global effects of the COVID-19 pandemic on the incidence of HZ.
Methods
The literature search was performed in October 2021 using PubMed and Embase. The search string was herpes zoster AND COVID-19. Publications were manually reviewed; case reports were removed.
Results
Three retrospective studies reported the risk of HZ following COVID-19 disease. One study (Bhavsar, 2021) used two US databases and found higher risk of HZ following COVID-19 disease (relative risk [RR]=1.15) and COVID-19 hospitalisation (RR = 1.21), respectively. A strong association between HZ and COVID-19 disease (RR = 5.27) was also reported in a study of the University of Florida patient registry (Katz, 2021). The third study (Barda, 2021) reported no association between COVID-19 disease and risk of HZ (RR = 0.82). In two of the three observational studies in Israel (Furer, 2021 and Barda, 2021), the incidence of HZ was increased following COVID-19 vaccination. The third study (Shasha, 2021) found no association (RR = 1.07). Other studies included a report in Brazil (Maia, 2021) that demonstrated a 35% increase in HZ diagnoses during the pandemic versus pre-pandemic and a published model (La, 2021) that estimated the declining uptake of recombinant zoster vaccine in the US may result in 63,117 avoidable HZ cases in those who remain unvaccinated in 2021.
Conclusions
Emerging data suggest that the COVID-19 pandemic may have increased the risk of HZ and negatively impacted HZ vaccine uptake. Therefore, there is an important need to increase awareness of HZ and HZ vaccination during the pandemic.
Key messages
• There is a need to increase awareness of HZ and HZ vaccination during the COVID-19 era.
• Further studies are needed to fully understand the impact of COVID-19 on the risk of HZ.
Collapse
Affiliation(s)
- N Lecrenier
- Global Medical Affairs , GlaxoSmithKline, Wavre, Belgium
| | - R Parikh
- Global Medical Affairs , GlaxoSmithKline, Wavre, Belgium
| | - C Wang
- Epidemiology, GlaxoSmithKline , Rockville, USA
| | - D Curran
- Value Evidence , GlaxoSmithKline, Wavre, Belgium
| | - R Widenmaier
- Global Medical Affairs , GlaxoSmithKline, Rockville, USA
| |
Collapse
|
6
|
Parikh R, Konstantinidis I, O'Sullivan DM, Farber HW. Pulmonary Hypertension in patients with Interstitial Lung Disease: a tool for early detection. Pulm Circ 2022; 12:e12141. [PMID: 36225536 PMCID: PMC9531548 DOI: 10.1002/pul2.12141] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Revised: 08/25/2022] [Accepted: 09/16/2022] [Indexed: 11/24/2022] Open
Abstract
Pulmonary hypertension (PH) complicates the treatment of interstitial lung disease (ILD) patients resulting in poor functional status and worse outcomes. Early recognition of PH in ILD is important for initiating therapy and considering lung transplantation. However, no standard exists regarding which patients to screen for PH‐ILD or the optimal method to do so. The aim of this study was to create a risk assessment tool that could reliably predict PH in ILD patients. We developed a PH‐ILD Detection tool that incorporated history, exam, 6‐min walk distance, diffusion capacity for carbon monoxide, chest imaging, and cardiac biomarkers to create an eight‐component score. This tool was analyzed retrospectively in 154 ILD patients where each patient was given a score ranging from 0 to 12. The sensitivity (SN) and specificity (SP) of the PH‐ILD Detection tool and an area‐under‐the‐curve (AUC) were calculated. In this cohort, 74 patients (48.1%) had PH‐ILD. A score of ≥6 on the PH‐ILD Detection tool was associated with a diagnosis of PH‐ILD (SN: 86.5%; SP: 86.3%; area‐under‐the‐curve: 0.920, p < 0.001). The PH‐ILD Detection tool provides high SN and SP for detecting PH in ILD patients. With confirmation in larger cohorts, this tool could improve the diagnosis of PH in ILD and may suggest further testing with right heart catheterization and earlier intervention with inhaled treprostinil and/or lung transplant evaluation.
Collapse
Affiliation(s)
- R Parikh
- Division of Pulmonary, Critical Care and Sleep Hartford Hospital Hartford CT
| | - I Konstantinidis
- Department of Internal Medicine University of Connecticut Farmington CT
| | - DM O'Sullivan
- Department of Research Administration Hartford HealthCare Hartford CT
| | - HW Farber
- Division of Pulmonary, Sleep and Critical Care Medicine Tufts Medical Center Boston MA
| |
Collapse
|
7
|
Parikh R, Shamimi-Noori S, Reddy S, Gade T, Nadolski G, Hunt S. Abstract No. 284 Demographic trends in female interventional radiology trainees with the advent of the integrated interventional radiology residency: a 12-month update. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
8
|
Parra E, Adriani M, Freitas Pinto Lima C, Li J, Haymaker C, Parikh R, Bernicker E, Davar D, Chaudhry A, Stevenson A, Badham C, Fyvie G, Chisamore M, Pant S. 1024P Baseline biomarkers associated with clinical benefit in patients with solid tumors refractory to immune checkpoint inhibitors (ICIs) treated with live biotherapeutic MRx0518 in combination with pembrolizumab. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1408] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
Jones N, Francis J, Parikh R, Shaath M. 102 Peer Teaching in Hip Fracture: Responding to the Medical Needs of Surgical Patients and Educational Needs of Junior Doctors. Br J Surg 2021. [DOI: 10.1093/bjs/znab134.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Introduction
Fractured Neck of Femur (FNOF) patients are complex. A mortality project identified topics for a peer-led teaching programme.
Method
Eight bite-sized case-based sessions were devised, to provide a framework to approach the following topics: Anaemia, delirium/dementia, ECG abnormalities, metastatic cancer, osteoporosis, renal disease, respiratory disease, and vascular complications. Attendees were asked to complete pre- and post- teaching programme questionnaires using a Likert Scale to indicate agreement with statements relating to the topic areas chosen (1=strongly disagree and 5=strongly agree).
Result
Pre-programme questionnaire: respondents were neutral (average 3.04) when asked whether topic areas were currently “well managed”. Attendees lacked confidence, indicating preparedness as neutral (average 3.35). Trainees agreed that they would benefit from teaching (average 4.56).
Post-programme questionnaire: increased confidence was reported when considering preparedness (average 4.3). Attendees felt the teaching programme was “accessible” and the “topics well-chosen”. 100% of attendees regarded the teaching as ‘excellent’ or ‘very-good’.
Conclusions
Matching patient needs to an educational programme is important.
The “bite-sized” nature of the programme paired with case-based learning increased confidence. A peer-led teaching programme is a positive response to themes emerging from morbidity and mortality reviews.
Collapse
Affiliation(s)
- N Jones
- Royal Oldham Hospital, Northern Care Alliance, Manchester, United Kingdom
| | - J Francis
- Royal Oldham Hospital, Northern Care Alliance, Manchester, United Kingdom
| | - R Parikh
- Royal Oldham Hospital, Northern Care Alliance, Manchester, United Kingdom
| | - M Shaath
- Royal Oldham Hospital, Northern Care Alliance, Manchester, United Kingdom
| |
Collapse
|
10
|
Parikh R, Dagli M. Abstract No. 517 Virtual follow-up of percutaneous drains placed in interventional radiology during the COVID-19 pandemic. J Vasc Interv Radiol 2021. [PMCID: PMC8079617 DOI: 10.1016/j.jvir.2021.03.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
11
|
Bhatia K, Columb M, Bewlay A, Eccles J, Hulgur M, Jayan N, Lie J, Verma D, Parikh R. The effect of COVID-19 on general anaesthesia rates for caesarean section. A cross-sectional analysis of six hospitals in the north-west of England. Anaesthesia 2020; 76:312-319. [PMID: 33073371 DOI: 10.1111/anae.15313] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/11/2020] [Indexed: 12/16/2022]
Abstract
At the onset of the global pandemic of COVID-19 (SARS-CoV-2), guidelines recommended using regional anaesthesia for caesarean section in preference to general anaesthesia. National figures from the UK suggest that 8.75% of over 170,000 caesarean sections are performed under general anaesthetic. We explored whether general anaesthesia rates for caesarean section changed during the peak of the pandemic across six maternity units in the north-west of England. We analysed anaesthetic information for 2480 caesarean sections across six maternity units from 1 April to 1 July 2020 (during the pandemic) and compared this information with data from 2555 caesarean sections performed at the same hospitals over a similar period in 2019. Primary outcome was change in general anaesthesia rate for caesarean section. Secondary outcomes included overall caesarean section rates, obstetric indications for caesarean section and regional to general anaesthesia conversion rates. A significant reduction (7.7 to 3.7%, p < 0.0001) in general anaesthetic rates, risk ratio (95%CI) 0.50 (0.39-0.93), was noted across hospitals during the pandemic. Regional to general anaesthesia conversion rates reduced (1.7 to 0.8%, p = 0.012), risk ratio (95%CI) 0.50 (0.29-0.86). Obstetric indications for caesarean sections did not change (p = 0.17) while the overall caesarean section rate increased (28.3 to 29.7%), risk ratio (95%CI) 1.02 (1.00-1.04), p = 0.052. Our analysis shows that general anaesthesia rates for caesarean section declined during the peak of the pandemic. Anaesthetic decision-making, recommendations from anaesthetic guidelines and presence of an on-site anaesthetic consultant in the delivery suite seem to be the key factors that influenced this decline.
Collapse
Affiliation(s)
- K Bhatia
- Department of Anaesthesia and Peri-operative Medicine, University of Manchester, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK
| | - M Columb
- Department of Anaesthesia, Peri-operative and Intensive Care Medicine, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
| | - A Bewlay
- Department of Anaesthesia, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK
| | - J Eccles
- Department of Anaesthesia, Royal Oldham Hospital, Oldham Care Organisation, Northern Care Alliance NHS Group, Oldham, UK
| | - M Hulgur
- Department of Anaesthesia, Royal Albert Edward Infirmary, Wrightington, Wigan and Leigh NHS Hospital NHS Foundation Trust, Wigan, UK
| | - N Jayan
- Department of Anaesthesia, Royal Albert Edward Infirmary, Wrightington, Wigan and Leigh NHS Hospital NHS Foundation Trust, Wigan, UK
| | - J Lie
- Department of Anaesthesia, Burnley General Teaching Hospital, East Lancashire Hospitals NHS Trust, Blackburn, UK
| | - D Verma
- Department of Anaesthesia, Liverpool Women's Hospital, Liverpool Women's Hospital NHS Foundation Trust, Liverpool, UK
| | - R Parikh
- Department of Anaesthesia, Liverpool Women's Hospital, Liverpool Women's Hospital NHS Foundation Trust, Liverpool, UK
| |
Collapse
|
12
|
Fleming C, Parikh R, Faruqi A, Contrera K, Xiong D, Rybicki L, Woody N, Joshi N, Greskovich J, Chute D, Ku J, Prendes B, Lamarre E, Lorenz R, Scharpf J, Burkey B, Schwartzman L, Geiger J, Adelstein D, Koyfman S. A Comparison Of Prognostic Factors For Survival After Distant Metastasis In HPV+ And HPV- Head And Neck Cancers. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
13
|
Ganatra S, Abraham S, Parikh R, Kamenetsky D, Patel R, Dani S, Chaudhry G, Resnic F, Shah S, Venesy D, Patten R, Neilan T, Reynolds M, Hook B, Nohria A. Efficacy and safety of catheter ablation for atrial fibrillation in patients with cancer. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3278] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Atrial fibrillation (AF) is the most common arrhythmia in patients with cancer. Management of AF in patients with cancer poses unique challenges. Long-term use of antiarrhythmic drug (AAD) therapy lacks evidence of efficacy in this population and poses risk of drug interactions. Catheter ablation is a well-established treatment modality for AAD resistant symptomatic AF and in patients with heart failure. Nevertheless, the effectiveness and safety of catheter ablation in patients with cancer is not well established.
Method
We retrospectively analyzed consecutive patients who underwent catheter ablation for AF, with either history of cancer (other than non-melanoma skin cancer) within 5-years prior or exposure to systemic anthracycline and/or thoracic radiation therapy at any time.
Results
The study included 162 patients. The mean age was 65.5 (26–84 years) years and 50% were female. Overall 133 (82%) patients had freedom from AF at 12 months following ablation. Of these 74 (54%) required post-ablation AAD, 18 (13.5%) required another ablation within the first 12 months and 9 (6.7%) required both AAD and a second ablation to maintain sinus rhythm. There were 14 adverse events (8.6%); 5 access site and 4 non-access site bleeding, 2 strokes, 2 cardiac tamponade and 1 pulmonary vein stenosis with ≈1% serious complications.
Conclusion
The success of catheter ablation for AF and the incidence of procedure related complications in patients with a history of recent cancer or prior exposure to cardiotoxic therapies are similar to that reported in patients without a history of cancer and hence if needed, it should be considered in select patients.
Funding Acknowledgement
Type of funding source: Private hospital(s). Main funding source(s): Dr. S Ganatra is supported by Lahey Physician Research Stipend Program.
Collapse
Affiliation(s)
- S Ganatra
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - S Abraham
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - R Parikh
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - D Kamenetsky
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - R Patel
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - S Dani
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - G Chaudhry
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - F Resnic
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - S Shah
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - D Venesy
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - R Patten
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - T Neilan
- Massachusetts General Hospital - Harvard Medical School, Boston, United States of America
| | - M Reynolds
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - B Hook
- Lahey Hospital & Medical Center, Burlington, United States of America
| | - A Nohria
- Brigham and Women'S Hospital, Harvard Medical School, Boston, United States of America
| |
Collapse
|
14
|
Ganatra S, Redd R, Hayek S, Parikh R, Azam T, Yanik G, Spendley L, Nikiforow S, Jacobson C, Nohria A. Cardiovascular effects of chimeric antigen receptor t-cell therapy for refractory or relapsed non-hodgkin lymphoma. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Purpose
Cardiovascular complications of chimeric antigen receptor T-cell (CAR T-cell) therapy are poorly understood. We examined the incidence, predictors and impact of new or worsening cardiomyopathy in patients undergoing CAR T-cell therapy.
Methods
All patients with refractory or relapsed non-Hodgkin's lymphoma, undergoing CAR T-cell therapy at collaborative institutes underwent serial echocardiograms at baseline and within 7 days after developing high-grade cytokine release syndrome (CRS), and were followed for all-cause mortality. New or worsening cardiomyopathy was defined as a reduction in left ventricular ejection fraction (LVEF) >10% from baseline to <50% during the index hospitalization.
Results
Among 187 consecutive CAR T-cell therapy patients, 116 (50 Grade ≤1 CRS, 66 Grade ≥2 CRS) had >1 echocardiogram performed and were included in this analysis. The median age was 63 (range 19–80) years, 42% were women, 91% were Caucasian. A total of 12 (10.3%) patients developed new or worsening cardiomyopathy with a decline in LVEF from 58±6% to 36±7% within a median of 12.5 (range 2–24) days of CAR T-cell infusion. In multivariable analyses, older age, prior stem cell transplantation, baseline angiotensin-converting enzyme inhibitor use and CRS grade ≥2 were associated with the development of cardiomyopathy. Patients who developed cardiomyopathy were more likely to require vasopressor support (p=0.004) and mechanical ventilation (p=0.014). LVEF improved in 9/12 (75%) patients. CAR T-cell associated cardiomyopathy did not impact overall mortality or cancer response to CAR-T cell therapy.
Conclusions
Patients undergoing CAR T-cell therapy are at risk of developing cardiomyopathy and hemodynamic instability. Pre-CAR T-cell therapy cardiovascular risk stratification and echocardiogram surveillance during therapy should be considered for prompt identification and mitigation of cardiac complications.
Predictors of Cardiomyopathy Development
Funding Acknowledgement
Type of funding source: Private hospital(s). Main funding source(s): Anju Nohria, MD is supported by the Gelb Master Clinician Award at Brigham and Women's Hospital.
Collapse
Affiliation(s)
- S Ganatra
- Lahey Hospital and Medical Center, Burlington, United States of America
| | - R Redd
- Dana Farber Cancer Institute, Boston, United States of America
| | - S Hayek
- University of Michigan, Ann Arbor, United States of America
| | - R Parikh
- Lahey Hospital and Medical Center, Burlington, United States of America
| | - T Azam
- University of Michigan, Ann Arbor, United States of America
| | - G Yanik
- University of Michigan, Ann Arbor, United States of America
| | - L Spendley
- Dana Farber Cancer Institute, Boston, United States of America
| | - S Nikiforow
- Dana Farber Cancer Institute, Boston, United States of America
| | - C Jacobson
- Dana Farber Cancer Institute, Boston, United States of America
| | - A Nohria
- Dana Farber Cancer Institute, Boston, United States of America
| |
Collapse
|
15
|
Karpes JB, Lansom JD, Alshahrani M, Parikh R, Shamavonian R, Alzahrani NA, Liauw W, Morris DL. Repeat cytoreductive surgery with or without intraperitoneal chemotherapy for recurrent epithelial appendiceal neoplasms. BJS Open 2020; 4:478-485. [PMID: 32020757 PMCID: PMC7260401 DOI: 10.1002/bjs5.50262] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Accepted: 12/19/2019] [Indexed: 12/30/2022] Open
Abstract
Background With recurrence rates after primary cytoreductive surgery (CRS) in excess of 50 per cent, repeat CRS is being performed increasingly, but survival outcomes have not been reported widely. This study examined the outcomes following repeat CRS for appendiceal cancer with peritoneal surface malignancy (PSM), and evaluated its feasibility and safety. Methods A retrospective cohort of patients who had surgery between 1996 and 2018 were analysed. Patients who underwent a single CRS procedure with or without heated intraperitoneal chemotherapy (HIPEC) were compared with those who had multiple procedures with or without HIPEC. Perioperative morbidity and survival outcomes were analysed. Results Some 462 patients were reviewed, 102 of whom had repeat procedures. For high‐grade tumours, patients who had a single CRS procedure had significantly reduced overall survival (OS) compared with those who had repeat CRS (55·6 versus 90·7 months respectively; P = 0·016). For low‐grade tumours, there was no difference in OS (P = 0·153). When patients who had a single procedure were compared with those who had multiple procedures, there was no significant difference in major morbidity (P = 0·441) or in‐hospital mortality (P = 0·080). For multiple procedures, no differences were found in major morbidity (P = 0·262) or in‐hospital mortality (P = 0·502) when the first procedure was compared with the second. For low‐grade cancers, the peritoneal carcinomatosis index was a significant prognostic factor for OS (hazard ratio (HR) 1·11, 95 per cent c.i. 1·05 to 1·17; P < 0·001), whereas for high‐grade cancers repeat CRS (HR 0·57, 0·33 to 0·95; P = 0·033), complete cytoreduction score (HR 1·55, 1·01 to 2·40; P = 0·046) and presence of signet ring cells (HR 2·77, 1·78 to 4·30; P < 0·001) were all significant indicators of long‐term survival. Conclusion In selected patients presenting with PSM from epithelial appendiceal neoplasms, repeat CRS performed in high‐volume centres could provide survival benefits.
Collapse
Affiliation(s)
- J B Karpes
- Liver and Peritonectomy Unit, St George Hospital, Sydney, New South Wales, Australia.,St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| | - J D Lansom
- Liver and Peritonectomy Unit, St George Hospital, Sydney, New South Wales, Australia
| | - M Alshahrani
- Liver and Peritonectomy Unit, St George Hospital, Sydney, New South Wales, Australia
| | - R Parikh
- Liver and Peritonectomy Unit, St George Hospital, Sydney, New South Wales, Australia
| | - R Shamavonian
- Liver and Peritonectomy Unit, St George Hospital, Sydney, New South Wales, Australia.,St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| | - N A Alzahrani
- Liver and Peritonectomy Unit, St George Hospital, Sydney, New South Wales, Australia.,College of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia
| | - W Liauw
- Liver and Peritonectomy Unit, St George Hospital, Sydney, New South Wales, Australia.,Cancer Care Clinic, St George Hospital, Sydney, New South Wales, Australia
| | - D L Morris
- Liver and Peritonectomy Unit, St George Hospital, Sydney, New South Wales, Australia.,St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| |
Collapse
|
16
|
Parikh R, Michelson D, Sapru M, Sahu R, Singh A, Cuijpers P, Patel V. Priorities and preferences for school-based mental health services in India: a multi-stakeholder study with adolescents, parents, school staff, and mental health providers. Glob Ment Health (Camb) 2019; 6:e18. [PMID: 31531228 PMCID: PMC6737585 DOI: 10.1017/gmh.2019.16] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2019] [Revised: 05/31/2019] [Accepted: 07/10/2019] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Schools are important settings for increasing reach and uptake of adolescent mental health interventions. There is limited consensus on the focus and content of school-based mental health services (SBMHSs), particularly in low-resource settings. This study elicited the views of diverse stakeholders in two urban settings in India about their priorities and preferences for SBMHSs. METHODS We completed semi-structured interviews and focus group discussions with adolescents (n = 191), parents (n = 9), teachers (n = 78), school counsellors (n = 15), clinical psychologists/psychiatrists (n = 7) in two urban sites in India (Delhi and Goa). Qualitative data were obtained on prioritized outcomes, preferred content and delivery methods, and indicated barriers. RESULTS All stakeholders indicated the need for and acceptability of SBMHSs. Adolescents prioritized resolution of life problems and exhibited a preference for practical guidance. Parents and teachers emphasized functional outcomes and preferred to be involved in interventions. In contrast, adolescents' favored limited involvement from parents and teachers, was related to widespread concerns about confidentiality. Face-to-face counselling was deemed to be the most acceptable delivery format; self-help was less frequently endorsed but was relatively more acceptable if blended with guidance or delivered using digital technology. Structured sensitization was recommended to promote adolescent's engagement. Providers endorsed a stepped care approach to address different levels of mental health need among adolescents. CONCLUSION SBMHSs are desired by adolescents and adult stakeholders in this setting where few such services exist. Sensitization activities are required to support implementation. School counsellors have an important role in identifying and treating adolescents with different levels of mental health needs, and a suite of interventions is needed to target these needs effectively and efficiently.
Collapse
Affiliation(s)
- R. Parikh
- Sangath, C-1/52, 1st Floor, Safdarjung Development Area, New Delhi, Delhi, India
- Department of Clinical, Neuro and Developmental Psychology, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, van der Boechorstraat 1, Amsterdam, The Netherlands
| | - D. Michelson
- School of Psychology, University of Sussex, Falmer, Brighton, UK
| | - M. Sapru
- Evalueserve.com Private Limited, Tower 6, 8th Floor, Candor Gurgaon One Realty Projects Pvt. Ltd., IT/ITES SEZ, Candor TechSpace, Tikri, Sector-48, Gurgaon, Haryana, India
| | - R. Sahu
- Sangath, C-1/52, 1st Floor, Safdarjung Development Area, New Delhi, Delhi, India
| | - A. Singh
- International Rescue Committee, No 69/54, Oat Tha Phaya Street, Kyaikkasan Quarter, Bahan Township, Yangon, Myanmar
| | - P. Cuijpers
- Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, van der Boechorstraat 1, Amsterdam, The Netherlands
| | - V. Patel
- Sangath, C-1/52, 1st Floor, Safdarjung Development Area, New Delhi, Delhi, India
- Department of Global Health and Social Medicine, Harvard Medical School, 641, Huntington Avenue, Boston, MA, USA
| |
Collapse
|
17
|
Ludlam S, Khan J, Ganiyu A, Parikh R. 53TEACHING FOUNDATION YEAR TWO (FY2) DOCTORS ABOUT THE GERIATRIC GIANTS: CAN WE IMPROVE CONFIDENCE WITH COMPLEXITY? Age Ageing 2019. [DOI: 10.1093/ageing/afz057.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - J Khan
- The Royal Oldham Hospital
| | | | | |
Collapse
|
18
|
Warburton T, Rutherford L, Parikh R. 62MEMORIES OF ‘66 AT THE NATIONAL FOOTBALL MUSEUM: REMINISCENCE THERAPY TEACHING FOR REGISTRARS. Age Ageing 2019. [DOI: 10.1093/ageing/afz057.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | | | - R Parikh
- Royal Oldham Hospital
- University of Salford
| |
Collapse
|
19
|
Khan J, Ganiyu A, Ludlam S, Parikh R. 55RATIONAL PRESCRIBING: POLYPHARMACY AND OPTIMAL PRESCRIBING TEACHING FOR FOUNDATION YEAR TWO (FY2) DOCTORS. Age Ageing 2019. [DOI: 10.1093/ageing/afz057.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J Khan
- The Royal Oldham Hospital
| | | | | | | |
Collapse
|
20
|
Nelson RL, Go C, Darwish R, Gao J, Parikh R, Kang C, Mahajan A, Habeeb L, Zalavadiya P, Patnam M. Cesarean delivery to prevent anal incontinence: a systematic review and meta-analysis. Tech Coloproctol 2019; 23:809-820. [PMID: 31273486 DOI: 10.1007/s10151-019-02029-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Accepted: 06/20/2019] [Indexed: 12/21/2022]
Abstract
BACKGROUND Cesarean delivery (CD), is increasingly recommended as a mode of delivery that prevents the anal incontinence (AI) that arises in some women after vaginal delivery (VD). The assessment of the efficacy of CD in this regard was the subject of this systematic review. METHODS Searches were conducted in Medline, EMBASE and the Cochrane Library. Both randomized (RCTs) and non-randomized trials (NRTs) comparing the risk of sustained fecal and/or flatus incontinence after VD or CD were sought from 1966 to 1 January, 2019. Studies were eligible if they assessed AI more than 6 months after birth, and had statistical adjustment for at least one of the three major confounders for AI: age, maternal weight or parity. In addition, each study was required to contain more than 250 participants, more than 50 CDs and more than 25 cases of AI. Data after screening and selection were abstracted and entered into Revman for meta-analysis. Analyses were done for combined fecal and flatus incontinence (comAI), fecal incontinence (FI), gas incontinence (GI), CD before or during labor, time trend of incontinence after delivery, assessment of both statistical and clinical heterogeneity, parity and late incident AI. RESULTS Out of the 2526 titles and abstracts found, 24 eligible studies were analyzed, 23 NRTs and one RCT. These included women with 29,597 VDs and women with 6821 CDs. Among the primary outcomes, VD was found not to be a significant predictor of postpartum comAI compared to CD in 6 studies, incorporating 18,951 deliveries (OR = 0.74; 0.54-1.02). VD was also not a significant predictor of FI in 14 studies, incorporating 29,367 deliveries, (OR = 0.89; 0.76-1.05). VD was not a significant predictor of GI in six studies, incorporating 6724 deliveries (OR = 0.96; 0.79-1.18). The strength of the grading of recommendations, assessment, development and evaluations (GRADE) evidence for each of these was low for comAI and moderate for FI and GI (upgrade for lack of expected effect). Time trend FI showed incontinence at 3 months often resolved at 1 year. Other secondary analyses assessing parity, delayed incidence of FI, clinical and statistical heterogeneity, spontaneous VD only, late risk of incidence of AI, and CD in or prior to labor all had similar results as in the primary outcomes. CONCLUSIONS There are three components of pelvic floor dysfunction that are thought to be caused by VD and hopefully prevented by CD: AI, urinary incontinence and pelvic floor prolapse. Of these, AI was not found to be reliably prevented by CD in this review.
Collapse
Affiliation(s)
- R L Nelson
- Epidemiology/Biometry Division, University of Illinois School of Public Health, Chicago, IL, USA.
| | - C Go
- Honors College, University of Illinois at Chicago, Chicago, IL, USA
| | - R Darwish
- Honors College, University of Illinois at Chicago, Chicago, IL, USA
| | - J Gao
- Honors College, University of Illinois at Chicago, Chicago, IL, USA
| | - R Parikh
- Honors College, University of Illinois at Chicago, Chicago, IL, USA
| | - C Kang
- Honors College, University of Illinois at Chicago, Chicago, IL, USA
| | - A Mahajan
- Honors College, University of Illinois at Chicago, Chicago, IL, USA
| | - L Habeeb
- Honors College, University of Illinois at Chicago, Chicago, IL, USA
| | - P Zalavadiya
- Honors College, University of Illinois at Chicago, Chicago, IL, USA
| | - M Patnam
- Honors College, University of Illinois at Chicago, Chicago, IL, USA
| |
Collapse
|
21
|
Villanueva C, Doyle M, Parikh R, Manganas C. Patient Safety and Current Practice During Chest Drain Insertion. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.02.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
22
|
Pickavance E, Oates R, Parikh R. 11REFLECTIVE WRITING: A PEER TEACHING INTERVENTION FOR SPECIALITY REGISTRARS IN GERIATRIC MEDICINE. Age Ageing 2018. [DOI: 10.1093/ageing/afy123.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Desai MP, Sharma R, Riaz I, Sudhanshu S, Parikh R, Bhatia V. Newborn Screening Guidelines for Congenital Hypothyroidism in India: Recommendations of the Indian Society for Pediatric and Adolescent Endocrinology (ISPAE) - Part I: Screening and Confirmation of Diagnosis. Indian J Pediatr 2018; 85:440-447. [PMID: 29380252 DOI: 10.1007/s12098-017-2575-y] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2017] [Accepted: 12/13/2017] [Indexed: 12/29/2022]
Abstract
UNLABELLED The Indian Society for Pediatric and Adolescent Endocrinology has formulated locally relevant Clinical Practice Guidelines for newborn screening, diagnosis and management of primary congenital hypothyroidism (CH). RECOMMENDATIONS Screening should be done for every newborn using cord blood, or postnatal blood, ideally at 48 to 72 h of age. On this screen sample, neonates with TSH > 20 mIU/L serum units (or >34 mIU/L for samples taken between 24 to 48 h of age) should be recalled for confirmation. For screen TSH > 40 mIU/L, immediate confirmatory venous T4/FT4 and TSH, and for milder elevation of screen TSH, a second screening TSH at 7 to 10 d of age, should be taken. Preterm and low birth weight infants should undergo screening at 48-72 h postnatal age. Sick babies should be screened at least by 7 d of age. Venous confirmatory TSH >20 mIU/L before age 2 wk and >10 mIU/L after age 2 wk, with low T4 (<10 μg/dL) or FT4 (<1.17 ng/dL) indicate primary CH and treatment initiation. Imaging is recommended by radionuclide scintigraphy and ultrasonography after CH is biochemically confirmed but treatment should not be delayed till scans are performed. Levothyroxine is commenced at 10 to 15 μg/kg in the neonatal period. Serum T4/FT4 is measured at 2 wk and TSH and T4/FT4 at 1 mo, then 2 monthly till 6 mo, 3 monthly from 6 mo-3 y and every 3-6 mo thereafter. Babies with the possibility of transient congenital hypothyroidism should be re-evaluated at age 3 y, to assess the need for lifelong therapy.
Collapse
Affiliation(s)
- M P Desai
- Division of Pediatric Endocrinology, Bai Jerbai Wadia Hospital for Children, Institute of Child Health & Research Centre, Parel, Mumbai, India
| | - R Sharma
- Division of Pediatric Endocrinology, Department of Pediatrics, All India Institute of Medical Sciences, Room no. 3058, Teaching Block, New Delhi, 110029, India.
| | - I Riaz
- Department of Pediatrics, SAT Hospital, Government Medical College, Thiruvananthapuram, India
| | - S Sudhanshu
- Department of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
| | - R Parikh
- Division of Pediatric Endocrinology, Bai Jerbai Wadia Hospital for Children, Institute of Child Health & Research Centre, Parel, Mumbai, India
| | - V Bhatia
- Department of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
| |
Collapse
|
24
|
Mehta T, Desai N, Mehta K, Parikh R, Male S, Hussain M, Ollenschleger M, Spiegel G, Grande A, Ezzeddine M, Jagadeesan B, Tummala R, McCullough L. Outcomes of early carotid stenting and angioplasty in large-vessel anterior circulation strokes treated with mechanical thrombectomy and intravenous thrombolytics. Interv Neuroradiol 2018; 24:392-397. [PMID: 29697301 DOI: 10.1177/1591019918768574] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Introduction Proximal cervical internal carotid artery stenosis greater than 50% merits revascularization to mitigate the risk of stroke recurrence among large-vessel anterior circulation strokes undergoing mechanical thrombectomy. Carotid artery stenting necessitates the use of antiplatelets, and there is a theoretical increased risk of hemorrhagic transformation given that such patients may already have received intravenous thrombolytics and have a significant infarct burden. We investigate the outcomes of large-vessel anterior circulation stroke patients treated with intravenous thrombolytics receiving same-day carotid stenting or selective angioplasty compared to no carotid intervention. Materials and methods The study cohort was obtained from the National (Nationwide) Inpatient Sample database between 2006 and 2014, using International Statistical Classification of Diseases, ninth revision discharge diagnosis and procedure codes. A total of 11,825 patients with large-vessel anterior circulation stroke treated with intravenous thrombolytic and mechanical thrombectomy on the same day were identified. The study population was subdivided into three subgroups: no carotid intervention, same-day carotid angioplasty without carotid stenting, and same-day carotid stenting. Outcomes were assessed with respect to mortality, significant disability at discharge, hemorrhagic transformation, and requirement of percutaneous endoscopic gastronomy tube placement, prolonged mechanical ventilation, or craniotomy. Results This study found no statistically significant difference in patient outcomes in those treated with concurrent carotid stenting compared to no carotid intervention in terms of morbidity or mortality. Conclusions If indicated, it is reasonable to consider concurrent carotid stenting and/or angioplasty for large-vessel anterior circulation stroke patients treated with mechanical thrombectomy who also receive intravenous thrombolytics.
Collapse
Affiliation(s)
- T Mehta
- 1 Department of Neurology, University of Minnesota, Minneapolis, MN, USA
| | - N Desai
- 2 Department of Neurology, Hartford Hospital, Hartford, CT, USA
| | - K Mehta
- 3 Department of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - R Parikh
- 4 Department of Public Health, University of Minnesota, Minneapolis, MN, USA
| | - S Male
- 1 Department of Neurology, University of Minnesota, Minneapolis, MN, USA
| | - M Hussain
- 5 Department of Interventional Neuroradiology, Hartford Hospital, Hartford, CT, USA
| | - M Ollenschleger
- 5 Department of Interventional Neuroradiology, Hartford Hospital, Hartford, CT, USA
| | - G Spiegel
- 6 Department of Neuroradiology, University of Texas Health Sciences Center, Houston, TX, USA
| | - A Grande
- 7 Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA
| | - M Ezzeddine
- 1 Department of Neurology, University of Minnesota, Minneapolis, MN, USA
| | - B Jagadeesan
- 8 Department of Radiology, University of Minnesota, Minneapolis, MN, USA
| | - R Tummala
- 7 Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA
| | - L McCullough
- 9 Department of Neurology, University of Texas Health Sciences Center, Houston, TX, USA
| |
Collapse
|
25
|
John D, Parikh R. Cost-effectiveness of community screening for glaucoma in rural India: a decision analytical model. Public Health 2018; 155:142-151. [DOI: 10.1016/j.puhe.2017.11.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 11/07/2017] [Accepted: 11/08/2017] [Indexed: 10/18/2022]
|
26
|
Sadeghi S, Groshen S, Parikh R, Mortazavi A, Dorff T, Hoimes C, Pal S, Levine E, Doyle L, Quinn D, Newman E, Lara P. Phase II California Cancer Consortium trial of gemcitabine–eribulin combination (GE) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): tolerability and toxicity report (NCI-9653; 1UM1CA186717-01, NO1-CM-2011-00038). Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30706-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
27
|
Desai P, Parikh R, Deshpande R. 57. Total esophagectomy is not always necessary in the treatment of squamous carcinoma & adenocarcinoma of the distal third of the esophagus & the cardia. Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.06.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
28
|
Parikh R, Desai P. 311. Selection criteria for definitive chemo-radiotherapy (CT-RT) in low rectal cancers: A preliminary data from a single centre, India. Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.06.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
29
|
Chadha M, Domi M, Parikh R, Kolev V, Koulos J. The time interval of adjuvant radiation therapy is influenced by the primary surgical technique used in treatment of endometrial cancer. Gynecol Oncol 2016. [DOI: 10.1016/j.ygyno.2016.04.524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Parikh R, Wardle K. 47EMBEDDING MANAGEMENT AND LEADERSHIP INTO CLINICAL SUBJECT TEACHING: WHAT DO TRAINEES THINK? Age Ageing 2016. [DOI: 10.1093/ageing/afw029.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Parikh R, Wardle K. 46TRAINEES' PERCEPTIONS OF EXPERT PATIENT DEMENTIA TEACHING. Age Ageing 2016. [DOI: 10.1093/ageing/afw029.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Wardle K, Parikh R. 44SHOULD WE INTEGRATE THE HUMANITIES INTO THE DELIVERY OF GERIATRIC MEDICINE? A SURVEY OF TRAINING PROGRAMME DIRECTORS. Age Ageing 2016. [DOI: 10.1093/ageing/afw029.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Shah P, Swarnkar D, Parikh R. Development and characterization of microemulsion containing antihypertensive agent using factorial design. J Pharm Bioallied Sci 2012; 4:S69-70. [PMID: 23066212 PMCID: PMC3467821 DOI: 10.4103/0975-7406.94143] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Microemulsion which act as a carrier for drug having poor water solubility, were formulated by the use of excipients having safety of administration and solubility of drug component. The phase study was carried out using isopropyl myristate, cremophor-el, propylene glycol and water with different ratios of components. Microemulsion region was chosen on basis of area covered. The % oil and % surfactant were selected as the independent factors and particle size and viscosity were selected as the dependent factors for the 2(2) Full Factorial Design. The optimized formulation showed the overcoming of the dissolution barrier helping in the formulation and administration.
Collapse
Affiliation(s)
- P Shah
- Department of Pharmaceutics and Pharmaceutical Technology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, Ta: Petlad, Dist: Anand, Gujarat, India
| | | | | |
Collapse
|
34
|
Mathur A, Parikh R, Kendall W, Leone J, Huang J, Pearson H, Bowers V. Pediatric En-bloc Kidney Transplant-a Small But Viable Answer to Augment the Donor Pool. J Surg Res 2012. [DOI: 10.1016/j.jss.2011.11.791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
35
|
Abstract
Waist circumference has been widely used as the parameter of central obesity in defining metabolic syndrome. Global consensus definition of metabolic syndrome has suggested various race- and gender-specific cutoffs of waist circumference for quantifying central obesity. We have earlier proposed that using index of central obesity (ICO), the need for race- and gender-specific cutoffs may be obviated. We propose that waist circumference be supplanted with index of central obesity in all definitions of metabolic syndrome. Using index of central obesity a common cutoff of 0.5 applicable across races and genders might be obtained. Moreover, it will enhance the sensitivity of definition by diagnosing subjects who are shorter than general population. Among 258 male and 242 female diabetic patients, subjects with metabolic syndrome (defined as per gender-specific waist circumference cutoffs), were found to have a common lower range of index of central obesity suggesting that a common cutoff of waist circumference may be obtained. In another study from National Health and Nutrition Examination Survey database, replacing index of central obesity with waist circumference was found to enhance the specificity and sensitivity of definition of metabolic syndrome.
Collapse
|
36
|
Casciano R, Wang X, Liu Z, Parikh R, Strosberg J, Riechelmann R. 6616 POSTER Impact of Progression on Resource Utilization in the Treatment of NET. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71927-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
37
|
Casciano R, Wang X, Stern L, Liu Z, Parikh R, Riechelmann R, Cadiot G, Strosberg J. 6618 POSTER Cross-Sectional Analysis of Resource Utilization Among Patients With Neuroendocrine Tumours. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71929-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
38
|
Johnston SRD, Gelmon KA, Pivot XB, Gradishar WJ, Conner A, Kothari D, Legenne P, Leigh M, O'Rourke L, Parikh R. Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps105] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Abstract
The diagnosis of glaucoma is usually made clinically and requires a comprehensive eye examination, including slit lamp, applanation tonometry, gonioscopy and dilated stereoscopic evaluation of the optic disc and retina. Automated perimetry is obtained if glaucoma is suspected. This establishes the presence of functional damage and provides a baseline for follow-up. Imaging techniques are not essential for the diagnosis but may have a role to play in the follow-up. We recommend a comprehensive eye examination for every clinic patient with the objective of detecting all potentially sight-threatening diseases, including glaucoma.
Collapse
Affiliation(s)
- Ravi Thomas
- Queensland Eye Institute, Brisbane, Queensland.
| | | | | |
Collapse
|
40
|
Abstract
INTRODUCTION Prolongation of the QT interval is a risk factor for sudden death. Methadone treatment is a well-recognised cause of QT interval lengthening in adults. The effect of maternal methadone treatment on the QT interval of the newborn infant is not known. This is the first prospective study of corrected QT (QTc) interval in infants born to mothers receiving methadone. AIM To compare QTc interval in infants born to mothers receiving methadone therapy with healthy controls. METHOD Twenty-six term infants (median gestation 38 weeks, range 37-40) born to mothers on methadone therapy had ECG recordings on days 1, 2, 4 and 7. The QTc interval was calculated using the Bazzett formula. Results for days 1 and 2 were compared with healthy matched control infants born to mothers who were not receiving methadone. Results for days 4 and 7 were compared with published normal values. RESULTS In the methadone group, the QTc interval was significantly prolonged on days 1 and 2 of life. On days 4 and 7, this increase was no longer present. None of the infants in either group had any evidence of significant cardiac rhythm disturbance. CONCLUSION Maternal methadone therapy can cause transient prolongation of the QTc interval in newborn infants in the first 2 days of life. Newborns exposed to methadone are at risk of cardiac rhythm disturbances. Bradycardia, tachycardia or an irregular heart rate in an infant born to a mother on methadone treatment should prompt investigation with a 12-lead ECG.
Collapse
Affiliation(s)
- R Parikh
- Department of Neonatology, Birmingham Women's Hospital, Edgbaston, Birmingham, UK.
| | | | | | | | | |
Collapse
|
41
|
Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, Ro J, Schütte J, Oliva C, Parikh R, Preston A, Rosenlund J, Selzer M, Zembryki D, De Placido S. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2009; 21:474-480. [PMID: 19815649 DOI: 10.1093/annonc/mdp373] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The Lapatinib Expanded Access Program (LEAP) was designed to provide access to lapatinib plus capecitabine for HER2-positive metastatic breast cancer patients who previously received an anthracycline, a taxane, and a trastuzumab and had no other treatment options. PATIENTS AND METHODS LEAP opened globally and enrollment continued until lapatinib received regulatory approval in each participating country. Patients were assessed for progression-free survival (PFS) and overall survival (OS) and monitored for serious adverse events (SAEs). RESULTS As of 30 September 2008, 4283 patients from 45 countries enrolled in LEAP. The median treatment duration was 24.7 weeks. The most common drug-related SAEs were diarrhea (9.7%), vomiting (4.3%), and nausea (2.4%) and were mainly grade 3 or higher. The incidences of special interest SAEs were decreased left ventricle ejection fraction (0.5%), interstitial lung disease/pneumonitis (0.2%), and serious hepatobiliary events (0.4%). This safety profile is consistent with the overall lapatinib program. The median PFS and OS were 21.1 [95% confidence interval (CI) = 20.1-22.3] and 39.6 (95% CI = 37.7-40.7) weeks, respectively (n = 4006). Subgroup analysis showed longer PFS and OS in patients who had not received prior capecitabine. CONCLUSIONS These results demonstrate the safety and efficacy of lapatinib in a broader patient population compared with a clinical trial.
Collapse
Affiliation(s)
- G Capri
- Department of Medical Oncology, Fondazione IRCCS Istituto Tumori, Milano, Italy.
| | - J Chang
- Medical Oncology Program, RS McLaughlin Durham Regional Cancer Centre, Oshawa, Ontario, Canada
| | - S-C Chen
- Department of General Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan
| | - P Conte
- Department of Oncology and Hematology, Universita degli Studi di Modena e Reggio Emilia, Modena, Italy
| | - K Cwiertka
- Department of Oncology, Hospital Olomouc, Olomouc, Czech Republic
| | - G Jerusalem
- Department of Medical Oncology, CHU Liège Hospital du Sart-Tilman, Liège, Belgium
| | - Z Jiang
- Breast Cancer Department, The Hospital Associated With Military Medical Science, Beijing, China
| | - S Johnston
- Department of Medical Oncology, Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, UK
| | - B Kaufman
- Breast Cancer Unit, Sheba Medical Center, Ramat Gan, Israel
| | - J Link
- Breast Link Medical Group, Inc., Long Beach, CA, USA
| | - J Ro
- Breast and Endocrine Cancer Branch, National Cancer Center, Kyunggi-do, South Korea
| | - J Schütte
- Department of Hematology and Oncology, Marien Hospital Düsseldorf, Düsseldorf, Germany
| | - C Oliva
- Oncology Medicine Development Center, GlaxoSmithKline, Uxbridge, Middlesex, UK
| | - R Parikh
- Oncology Medicine Development Center, GlaxoSmithKline, Uxbridge, Middlesex, UK
| | - A Preston
- Oncology Medicine Development Center, GlaxoSmithKline, Collegeville, PA, USA
| | - J Rosenlund
- Oncology Medicine Development Center, GlaxoSmithKline, Collegeville, PA, USA
| | - M Selzer
- Oncology, Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Collegeville, PA, USA
| | - D Zembryki
- Oncology Medicine Development Center, GlaxoSmithKline, Collegeville, PA, USA
| | - S De Placido
- Department of Molecular and Clinical Oncology, Universita degli Studi di Napoli Federico II, Napoli, Italy
| |
Collapse
|
42
|
Ramlau R, Thomas M, Plummer R, Reck M, Heussel CP, Lau M, Parikh R, Kaneko T, Oliva C, Novello S. Phase I study of lapatinib, a dual-tyrosine kinase inhibitor, and pemetrexed in the second-line treatment of advanced or metastatic non-small cell lung cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19027 Background: Lapatinib is an oral, reversible small-molecule inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). EGFR overexpression is very common in non-small-cell lung cancer (NSCLC), ranging from 30% to 83%, whereas HER2 overexpression occurs in about 20%. Pemetrexed is currently given as second-line therapy and achieves a 9% response rate. The rationale for EGFR/HER2 inhibition in combination with pemetrexed is to demonstrate clinical synergy as previously shown with gemcitabine, another fluoropyrimidine pathway inhibitor. Methods: Eligible patients included those with stage IIIB or IV NSCLC and European Cooperative Oncology Group performance status of 0–2 following 1 previous chemotherapy treatment. Patients were treated in 3 escalating dose levels (DLs) of pemetrexed (given intravenously every 21 days) and daily lapatinib (DL 0: 400 mg/1,250 mg; DL 1: 500 mg/1,250 mg; DL 2: 500 mg/1,500 mg, respectively). A standard phase 1, 3+3 trial design was used. The primary objective was to determine the optimal treatment regimen. Results: Eighteen patients were treated (DL 0: n=4, DL 1: n=8; DL 2: n=6). The most common adverse events (any grade) were diarrhea (61%), rash (44%), fatigue (28%), nausea (28%), anemia (28%), anorexia (22%), vomiting (22%), dyspnea (17%), and neutropenia (17%). Grade 3/4 adverse events were lymphocytopenia (n=5) and neutropenia (n=5). Other related grade 3 events were diarrhea (n=2), nausea (n=1), decreased ejection fraction (n=1), and increased alkaline phosphatase (n=1). The optimal treatment regimen was determined as lapatinib 1250 mg given with 500 mg pemetrexed after occurrence of 3 dose-limiting toxicities during the first cycle in DL 2 (grade 3 diarrhea, grade 4 lymphocytopenia, and grade 3 mucositis). No further dose-limiting toxicities were observed in DL 0 or DL 1. Preliminary evidence of clinical activity was encouraging, with 3 patients showing partial response. Conclusions: The combination of lapatinib with pemetrexed is well tolerated; encouraging activity has been demonstrated in pretreated NSCLC patients and warrants further studies. [Table: see text]
Collapse
Affiliation(s)
- R. Ramlau
- Regional Lung Diseases Hospital, Poznan, Poland; University Hospital Heidelberg, Heidelberg, Germany; Northern Institute for Cancer Research, Newcastle, United Kingdom; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; University of Turin, Turin, Italy
| | - M. Thomas
- Regional Lung Diseases Hospital, Poznan, Poland; University Hospital Heidelberg, Heidelberg, Germany; Northern Institute for Cancer Research, Newcastle, United Kingdom; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; University of Turin, Turin, Italy
| | - R. Plummer
- Regional Lung Diseases Hospital, Poznan, Poland; University Hospital Heidelberg, Heidelberg, Germany; Northern Institute for Cancer Research, Newcastle, United Kingdom; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; University of Turin, Turin, Italy
| | - M. Reck
- Regional Lung Diseases Hospital, Poznan, Poland; University Hospital Heidelberg, Heidelberg, Germany; Northern Institute for Cancer Research, Newcastle, United Kingdom; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; University of Turin, Turin, Italy
| | - C. P. Heussel
- Regional Lung Diseases Hospital, Poznan, Poland; University Hospital Heidelberg, Heidelberg, Germany; Northern Institute for Cancer Research, Newcastle, United Kingdom; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; University of Turin, Turin, Italy
| | - M. Lau
- Regional Lung Diseases Hospital, Poznan, Poland; University Hospital Heidelberg, Heidelberg, Germany; Northern Institute for Cancer Research, Newcastle, United Kingdom; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; University of Turin, Turin, Italy
| | - R. Parikh
- Regional Lung Diseases Hospital, Poznan, Poland; University Hospital Heidelberg, Heidelberg, Germany; Northern Institute for Cancer Research, Newcastle, United Kingdom; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; University of Turin, Turin, Italy
| | - T. Kaneko
- Regional Lung Diseases Hospital, Poznan, Poland; University Hospital Heidelberg, Heidelberg, Germany; Northern Institute for Cancer Research, Newcastle, United Kingdom; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; University of Turin, Turin, Italy
| | - C. Oliva
- Regional Lung Diseases Hospital, Poznan, Poland; University Hospital Heidelberg, Heidelberg, Germany; Northern Institute for Cancer Research, Newcastle, United Kingdom; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; University of Turin, Turin, Italy
| | - S. Novello
- Regional Lung Diseases Hospital, Poznan, Poland; University Hospital Heidelberg, Heidelberg, Germany; Northern Institute for Cancer Research, Newcastle, United Kingdom; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; University of Turin, Turin, Italy
| |
Collapse
|
43
|
Parikh R, Faillace R, Hamdan A, Adinaro D, Pruden J, DeBari V, Bikkina M. An emergency physician activated protocol, 'Code STEMI' reduces door-to-balloon time and length of stay of patients presenting with ST-segment elevation myocardial infarction. Int J Clin Pract 2009; 63:398-406. [PMID: 19222625 DOI: 10.1111/j.1742-1241.2008.01920.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
INTRODUCTION National consensus guidelines recommend that ST-segment elevation myocardial infarction (STEMI) patients achieve a door-to-balloon time of < 90 min. We sought to determine if emergency physician initiated simultaneous activation of the cardiac catheterisation laboratory team and the on-call interventional cardiologist has any impact on reducing door-to-balloon-times at our hospital. METHODS A total of 72 consecutive STEMI patients were evaluated from January 2007 to December 2007. The emergency physician activated Code STEMI required concurrent activation of cardiac catheterisation personnel and the on-call interventional cardiologist by the emergency physician. These patients were compared with our staff cardiologist activated primary angioplasty protocol from January 2006 to December 2006 for 51 consecutive STEMI patients. The primary outcome was to measure median door-to-balloon time between both groups. Secondary end-points included the individual components of door-to-balloon times (i.e. door-to-ECG time), peak troponin-I level within 24 h, length of stay and all-cause in-hospital mortality. RESULTS Median door-to-balloon time decreased overall (112 vs. 74 min, p < 0.001). Of the three components of door-to-balloon time analysed, the ECG to cardiac catheterization laboratory time exhibited the largest area of improvement with 16 min absolute reduction in median door-to-balloon time. Median peak troponin levels (50 vs. 25 ng/ml, p < 0.001), and hospital length of stay (4 vs. 3 days, p < 0.01) decreased. We did not see any statistically significant difference in all-cause in-hospital mortality (p = 0.6). CONCLUSIONS Emergency physician activation of the Code STEMI significantly reduces door-to-balloon time to within national standards of care, and length of stay in STEMI patients.
Collapse
Affiliation(s)
- R Parikh
- Department of Cardiology, St. Joseph's Regional Medical Center, Paterson, NJ 07501, USA
| | | | | | | | | | | | | |
Collapse
|
44
|
Crown J, Burris H, Di Leo A, Jagiello-Gruszfeld A, Jones S, LoRusso P, Oliva C, Parikh R, Stein S, Koehler M. Tolerability of lapatinib in combination with taxanes (T) in 507 patients with breast cancer (BC). EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)70818-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
45
|
Crown JP, Burris HA, Jones S, Koch KM, Fittipaldo A, Parikh R, Koehler M. Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1027] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1027 Background: Lapatinib (L) is an oral, dual ErbB1/B2 tyrosine kinase inhibitor. T are mainstay of BC treatment. The side-effects seen with T in combination with gefitinib and erlotinib include neutropenia, diarrhea and rash. Based on preclinical synergy, early clinical studies with L and paclitaxel (P) or docetaxel (D) were studied. Methods: We summarize pharmacokinetics (PK) and preliminary safety data from 192 patients. Results: PK analysis for EGF10009 (q3w), show systemic exposure was increased for both L (21%) and P (23%) at doses of 1500mg daily and 175mg/m2/q3w, respectively. PK analysis in EGF10021 , (L 1250 mg & D 75 mg/m2 with prophylactic pegfilgrastim) indicated no significant effect on systemic exposure of either agent. Toxicities across all studies include i.e., for all patients = grade 3, neutropenia (7.3%), diarrhea (18.2%), rash (3.6%). The rate of adverse events for neutropenia and rash were similar to each agent alone, however diarrhea was more common. The frequency and severity of diarrhea was increased in studies EGF10009 and EGF102580 where no proactive treatment of diarrhea was introduced, whereas in EGF105764, with proactive treatment, currently no =grade 3 diarrhea has been reported. The data show that the combination of L and P has clinical activity (>70% RR reported in EGF102580). Conclusions: T plus L combinations have a predictable and manageable safety profile and clinical activity of P plus L combination was observed. Proactive diarrhea management is essential for these combinations. Based on the PK data, no dose adjustments are required, and any dose adjustments should be toxicity-based. Ongoing clinical studies investigating the combinations of L with T, and combinations of L with T plus trastuzumab will be reported in the future. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. P. Crown
- St. Vincent’s University Hospital, Dublin, Ireland; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Collegeville, PA
| | - H. A. Burris
- St. Vincent’s University Hospital, Dublin, Ireland; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Collegeville, PA
| | - S. Jones
- St. Vincent’s University Hospital, Dublin, Ireland; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Collegeville, PA
| | - K. M. Koch
- St. Vincent’s University Hospital, Dublin, Ireland; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Collegeville, PA
| | - A. Fittipaldo
- St. Vincent’s University Hospital, Dublin, Ireland; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Collegeville, PA
| | - R. Parikh
- St. Vincent’s University Hospital, Dublin, Ireland; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Collegeville, PA
| | - M. Koehler
- St. Vincent’s University Hospital, Dublin, Ireland; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Collegeville, PA
| |
Collapse
|
46
|
|
47
|
Levy EI, Sauvageau E, Hanel RA, Parikh R, Hopkins LN. Self-expanding versus balloon-mounted stents for vessel recanalization following embolic occlusion in the canine model: technical feasibility study. AJNR Am J Neuroradiol 2006; 27:2069-72. [PMID: 17110668 PMCID: PMC7977237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
BACKGROUND AND PURPOSE Despite advances in mechanical thrombolysis for acute stroke, recanalization rates remain approximately 50%-60%. Technologic improvements allowed safe intracranial delivery of stents. To study the feasibility of stent-assisted recanalization for acute stroke, we deployed self-expanding or balloon-mounted stents in 2- to 3.5-mm canine vessels acutely occluded with clot emboli. METHODS Six mongrel dogs were placed under general anesthesia. A guiding catheter was placed in the distal vertebral artery or an external carotid artery branch. A 7 x 3 mm (length x diameter) soft or hard clot was injected into the catheter and allowed to embolize distally; 20 vessels were successfully occluded. After systemic heparin anticoagulation, recanalization with a self-expanding stent was attempted in 11 vessels (5 occluded with soft clot; 6, with hard clot). Balloon-mounted stents were placed in an attempt to revascularize 9 vessels (4 occluded with soft clot; 5, with hard clot). Vessel recanalization was assessed as the primary end point. Side-branch occlusion and stent-induced vasospasm were also assessed. RESULTS Thrombolysis in Myocardial Infarction/Thrombolysis in Cerebral Infarction flow for 11 vessels treated with self-expanding stents versus 9 treated with balloon-mounted stents was as follows: grade 3, 91% of vessels versus 78% of vessels; grade 2, 0% versus 11%; grade 1, 9% versus 0%; grade 0, 0% versus 11%. Lower rates of spasm and side-branch occlusion were noticed with self-expanding stents. Grade 2/3 flow was achieved in 18/20 vessels (90%). CONCLUSIONS Excellent recanalization was demonstrated with both stents. Recanalization in self-expanding stents was achieved without pre- or post-balloon dilation. Stents may prove to be a useful adjunct for intra-arterial acute stroke treatment.
Collapse
Affiliation(s)
- E I Levy
- Department of Neurosurgery and Toshiba Stroke Research Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY 14209, USA
| | | | | | | | | |
Collapse
|
48
|
Hamid R, Rotshteyn Y, Rabadi L, Parikh R, Bullock P. Comparison of alamar blue and MTT assays for high through-put screening. Toxicol In Vitro 2004; 18:703-10. [PMID: 15251189 DOI: 10.1016/j.tiv.2004.03.012] [Citation(s) in RCA: 374] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/25/2004] [Indexed: 10/26/2022]
Abstract
The performance of alamar blue and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) cell viability assays in a high through-put format were compared. A total of 117 drugs chosen for their wide range of therapeutic areas were screened at 10 microM using both assays in human hepatoma cell line HepG2. Except for terfenadine and astemizole, which performed consistently in both assays, the alamar blue assay was slightly more sensitive than the MTT assay for most compounds. The MTT assay was less sensitive detecting an effect for daunorubicin and trifluoperazine. Seven drugs, astemizole, daunorubicin, ellipticine, fluphenazine, terfenadine, thioridazine and trifluoperazine, had percent viability results of 55% or less in the alamar blue assay at the single point screen. These were re-tested in both assays for reconfirmation of cytotoxicity and determination of the EC50 values. Except for daunorubicin, the EC50 values were comparable in both assays. Based on these results and the Z'-factor assessment of assay quality, both assays provided useful information to identify in vitro cytotoxic drugs at early stages of drug candidate selection. However, careful interpretation of data is warranted due to the possibility of false positive or negative results caused by inducers and/or inhibitors of metabolic enzymes that are responsible for transformation of cell toxicity end points, as we demonstrated using dicumarol.
Collapse
Affiliation(s)
- R Hamid
- Discovery Support, Purdue Pharma L.P., 444 Saw Mill River Road, Ardsley, NY 10502, USA.
| | | | | | | | | |
Collapse
|
49
|
Gan H, Song J, Parikh R, Kang J, Evers B, Chung D. Signal transduction pathways involved in oxidative stress-induced intestinal epithelial cell injury. J Surg Res 2004. [DOI: 10.1016/j.jss.2004.07.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
50
|
Thomas R, George R, Parikh R, Muliyil J, Jacob A. Five year risk of progression of primary angle closure suspects to primary angle closure: a population based study. Br J Ophthalmol 2003; 87:450-4. [PMID: 12642309 PMCID: PMC1771602 DOI: 10.1136/bjo.87.4.450] [Citation(s) in RCA: 159] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
AIM To report progression of primary angle closure suspects (PACS) to primary angle closure (PAC) at the 5 year follow up of a population based sample. METHODS 82 of 118 PACS who could be contacted and 110 randomly selected normals from a population based survey in 1995 were invited for a follow up examination in 2000. Progression to PAC was based on the development of raised IOP or synechiae in a PACS. RESULTS 50 of the 82 PACS contacted were examined. 11 (22%; 95% CI 9.8 to 34.2) developed PAC (seven synechial and four appositional); all were bilateral PACS. Two of 50 people previously diagnosed as PACS were reclassified as normal. One person among the 110 normals progressed to PAC. The relative risk of progression among PACS was 24 (95% CI 3.2 to 182.4). There was no significant difference in axial length, anterior chamber depth, or lens thickness between those who progressed and those who did not. None of the patients developed optic disc or field damage attributable to angle closure. One angle closure suspect was diagnosed to have normotensive glaucoma. CONCLUSION In this population based study of PACS the 5 year incidence of PAC was 22%; none developed functional damage. Bilateral PACS was a clinical risk factor for progression.
Collapse
Affiliation(s)
- R Thomas
- LV Prasad Eye Institute, Hyderabad, India Schell Eye Hospital, Department Ophthalmology, Christian Medical College, Vellore, India.
| | | | | | | | | |
Collapse
|